Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Ocumension Therapeutics
  6. News
  7. Most relevant
    1477   KYG674111011

OCUMENSION THERAPEUTICS

(1477)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about OCUMENSION THERAPEUTICS
01/05Ocumension Therapeutics Enrolls First Patient in Clinical Trial of Dry Eye Treatment in..
MT
01/04Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-..
CI
2021Nicox Screens First Patient in China in Late-Stage Trial For Glaucoma Treatment
MT
2021OCUMENSION THERAPEUTICS : China Approves Clinical Trial of Ocumension Therapeutics Drug fo..
MT
2021Ocumension Therapeutics Announces Approval Received for Clinical Trial of Class I New D..
CI
2021Ocumension Therapeutics Reports Unaudited Consolidated Earnings Results for the Six Mon..
CI
2021OCUMENSION THERAPEUTICS' : Phase 3 Clinical Trial Application for Eye Inflammation Treatme..
MT
2021Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical ..
CI
2021OCUMENSION THERAPEUTICS : Snaps Up Interests In Two Eye Drugs In China From Novartis
MT
2021OCUMENSION THERAPEUTICS : Acquires all the Equity Interests in Two Ophthalmic Products Mai..
PR
2021OCUMENSION THERAPEUTICS : Unit Buying Chinese Licenses for Ocular Itch Treatment for $35 M..
MT
2021Ocumension Therapeutics Announces Interim Earnings Results for the 6 Months Ended 30 Ju..
CI
2021OCUMENSION THERAPEUTICS : Announces 2021 Interim Results
PR
2021Ocumension Therapeutics Announces the Group's Product, OT-502 Approves for Carrying Out..
CI
2021Ocumension Therapeutics Issues Warrants to Nasdaq-Listed Drugmaker
MT
2021OCUMENSION THERAPEUTICS : Notice of extraordinary general meeting
PU
2021OCUMENSION THERAPEUTICS : Wins Regulatory Nod to Start Phase III Trial of Myopia Drug in U..
MT
2021Ocumension Therapeutics MHRA Approval Received for Phase III Clinical Trial of OT-101 i..
CI
2021Ocumension Therapeutics Announces Re-Designation of Executive Directors as Non-Executiv..
CI
2021OCUMENSION THERAPEUTICS : Wins Regulatory Nod to Start Phase III Trial of Myopia Drug in C..
MT
2021Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial ..
CI
2021OCUMENSION THERAPEUTICS : Phase III Clinical Trial Application for Eye Drops Accepted in C..
MT
2021Certain Ordinary Shares of Ocumension Therapeutics are subject to a Lock-Up Agreement E..
CI
2021Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 Approves in China
CI
2021OCUMENSION THERAPEUTICS : Wins Nod to Import Post-Op Drug in China's Hainan Province; Shar..
MT
2021GLOBAL MARKETS LIVE : WM Morrison, IBM, Didi...
2021NICOX : to Get $2 Million from Ocumension Under Amended Zerviate License Deal
MT
2021OPKO Health to Develop and Commercialize RAYALDEE in Greater China with Nicoya Therapeu..
AQ
2021OCUMENSION THERAPEUTICS : Controlling Shareholders Cut Stake in Firm; Shares Jump 6%
MT
2021OCUMENSION THERAPEUTICS' : Clinical Trial Application for Eye Drug Accepted in UK; Shares ..
MT
2021Ocumension Therapeutics Announces Clinical Trial Authorization for Initiatinga Phase II..
CI
2021OCUMENSION THERAPEUTICS : Voluntary announcement ind application received for a phase iii ..
PU
2021OCUMENSION THERAPEUTICS : Chinese Regulators Accept Ocumension Therapeutics' Phase Three T..
MT
2021Ocumension Therapeutics Announces Investigational New Drug Application for Initiating A..
CI
2021OCUMENSION THERAPEUTICS : Completion of the transactions under share purchase agreement
PU
2021OCUMENSION THERAPEUTICS : Wins Nod to Study Children's Myopia Drug in US; Shares Rally 10%
MT
2021OCUMENSION THERAPEUTICS : Voluntary announcement approval for commencement of initial pedi..
PU
2021Ocumension Therapeutics announces Approval for Commencement of Initial Pediatric Study ..
CI
2021Ocumension Therapeutics Strikes $20 Million Licensing, Investment Deal with US Drugmake..
MT
2021OCUMENSION THERAPEUTICS : (i) discloseable transactions relating to the exclusive license ..
PU
2021ALIMERA SCIENCES : Grants Iluvien License to Ocumension Therapeutics
MT
2021OCUMENSION THERAPEUTICS : Chinese Regulators Accept Ocumension Therapeutics' Eye Drug Appl..
MT
2021OCUMENSION THERAPEUTICS : Voluntary announcement first patient enrolled in the phase iii c..
PU
2021OCUMENSION THERAPEUTICS : Voluntary announcement new drug application for ot-401 accepted ..
PU
2021Ocumension Therapeutics Announces New Drug Application for Ot-401 Accepted by the Natio..
CI
2021OCUMENSION THERAPEUTICS : Widens Loss for 2020 on High Expenses
MT
2021Ocumension Therapeutics Reports Revenue Results for the Year Ended 31 December 2020
CI
2021OCUMENSION THERAPEUTICS : Change of non-executive director
PU
2021Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2..
CI
2021Ocumension Therapeutics Announces Board Changes
CI
2021OCUMENSION THERAPEUTICS : Added to Shenzhen-Hong Kong Trading Link; Shares Gain Over 3%
MT
2021OCUMENSION THERAPEUTICS : Voluntary announcement inclusion of the shares of the company in..
PU
2021Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phas..
CI
2021OCUMENSION THERAPEUTICS : Secures Regulatory Nod to Start Phase III Study of Eye Drug in C..
MT
2021OCUMENSION THERAPEUTICS : Voluntary announcement second phase iii clinical trial of ot-301..
PU
2021Ocumension Therapeutics Announces Second Phase III Clinical Trial of OT-301 Approved in..
CI
2021OCUMENSION THERAPEUTICS : Voluntary announcement selection of the shares of the company as..
PU
2021OCUMENSION THERAPEUTICS : Wins Regulatory Nod to Start Phase III Trial of Eye Drops in US
MT
2021Ocumension Therapeutics Announces Investigational New Drug Approval for Initiating A Mu..
CI
2021OCUMENSION THERAPEUTICS : Luye Pharma Dose First Patient in Phase III Trial of Eye Drug in..
MT
2021Ocumension Therapeutics Announces Phase III Clinical Trial of the Recently In-Licensed ..
CI
2021OCUMENSION THERAPEUTICS : Seeks $102 Million from Top-Up Placement
MT
2021Certain Ordinary Shares of Ocumension Therapeutics are subject to a Lock-Up Agreement E..
CI
2021OCUMENSION THERAPEUTICS : Acquires Three Million Shares of EyePoint Pharmaceuticals
MT
2020OCUMENSION THERAPEUTICS : Doses First Patient in Phase III Trial of Eye Drops in China; Sh..
MT
2020Ocumension Therapeutics Announces First Patient Enrolled in the Phase III Clinical Tria..
CI
2020Ocumension Therapeutics Core Product,OT-401 Approves to Carry Out the Real World Study ..
CI
2020Ocumension Therapeutics Announces Address Change
CI
2020OCUMENSION THERAPEUTICS(SEHK : 1477) added to S&P Global BMI Index
CI
2020OCUMENSION THERAPEUTICS : Shares Jump 3% on Real World Study for Eye Inflammation Drug
MT
2020Ocumension Therapeutics Initiates the Real World Study of Its Core Product, OT-401 in B..
CI
2020Ocumension Therapeutics Announces Initiation of Second Phase III Clinical Trial of OT-3..
CI
2020Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases
CI
2020Ocumension Therapeutics Receives Approval by Chinese Authorities for Local Start of Mon..
CI
2020China Approves Phase III Clinical Trial of OT-301 (NCX 470) of Ocumension Therapeutics
CI
1  2Next